Journal
JOURNAL OF CONTROLLED RELEASE
Volume 102, Issue 2, Pages 509-520Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2004.10.005
Keywords
transdermal drug delivery; naltrexone; prodrugs; guinea pig; pharmacokinetics
Funding
- NIDA NIH HHS [R01DA13425] Funding Source: Medline
Ask authors/readers for more resources
Naltrexone (NTX) is a potent competitive antagonist with high affinity for the g-opioid receptor. Therapeutically, NTX is used for the treatment of alcohol dependence and opioid addiction; however, it does not have the ideal physicochemical properties necessary to achieve therapeutic plasma concentrations via the transdermal route. The aim of the present investigation was to evaluate the in vivo transdermal delivery of three 3-O-alkyl ester prodrugs of NTX, including NTX-3-O-acetate (ACE-NTX), NTX-3-O-propionate (PROP-NTX), and NTX-3-O-hexanoate (HEX-NTX) in hairless guinea pigs. The pharmacokinetic parameters for NTX and the 3-O-alkyl ester prodrugs of NTX were determined after intravenous drug administration and topical drug application of transdermal therapeutic systems (TTS) in guinea pigs. The results of the in vivo studies showed mean steady-state plasma concentrations of NTX from NTX, ACE-NTX, PROP-NTX and HEX-NTX at 4.2, 25.2, 16.0, and 8.3 ng/mL, respectively. These NTX plasma concentrations were maintained for 48 h. The results of these in vivo studies demonstrated that ACE-NTX and PROP-NTX prodrugs of NTX were the most promising drug candidates for transdermal delivery. (C) 2004 Elsevier B.V. All fights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available